EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy

Chafic Karam iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Chafic Karam. Beteiligte Einrichtung: Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neurofilament Proteins, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introductions/Aims The clinical utility of serum neurofilament light chain (sNfL) in the evaluation and management of peripheral neuropathy (PN) remains poorly defined. This study aimed to evaluate the utility of sNfL for diagnosing PN, assessing disease activity, and monitoring treatment response using a commercially available assay.

Methods

This was a retrospective cohort study at the University of Pennsylvania between June 2024 and March 2025. Patients with, or at risk for, PN who underwent sNfL testing were included. Demographics, PN etiology, clinical findings, and sNfL levels were analyzed.

Results

One hundred and twenty‐eight patients were included: 41 with chronic inflammatory demyelinating polyneuropathy (CIDP), 36 with transthyretin amyloidosis (ATTR), 13 with vasculitic PN, 13 with Charcot–Marie–Tooth disease (CMT), 6 with multifocal motor neuropathy (MMN), 4 with anti‐MAG neuropathy, 4 with Guillain‐Barré syndrome (GBS), and 11 with other PN types. Of these, 113 had definite large fiber PN; 14 were asymptomatic TTRv carriers, and one had small fiber neuropathy. Elevated sNfL levels were observed in 31 patients (24%). The odds ratio of having elevated sNfL in treatable vs. non‐treatable PN was 28.33 (95% CI: 5.04–159.18). Among CIDP and ATTRv‐PN patients, sNfL was most often elevated in treatment‐naïve or refractory cases and decreased with treatment.

Discussion

Routine sNfL testing is warranted in selected patients with PN, such as treatment‐naïve or refractory CIDP, active vasculitic PN, and ATTRv‐PN. Elevated sNfL in patients with PN should prompt evaluation for a potentially treatable cause and may offer useful adjunctive information to support clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsPeripheral Nervous System DiseasesHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultBiomarkersAged, 80 and overPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingCohort StudiesAmyloid Neuropathies, Familial

Stichwörter der Autor:innen

ATTRvCIDPCMTMAGMMNhATTRneurofilament light chainperipheral neuropathyvasculitic neuropathy

Substanzen

Neurofilament Proteinsneurofilament protein LBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Chafic Karam

Zitieren

APA

Karam, C. (2026). Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. Muscle & Nerve. https://doi.org/10.1002/mus.70073

Vancouver

Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. Muscle & Nerve. 2026. doi:10.1002/mus.70073

BibTeX
@article{Karam2026,
  author = {Karam, Chafic},
  title = {Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70073}
}
Kostenlos starten →